CD79A and infection: Furthermore, nasal antibodies after breakthrough infection with Omicron BA.1 or BA.2 virus possess neutralizing activity against BA.5 and Delta viruses (27), indicating that mucosal S-IgA has high cross-protective activity against SARS-CoV-2 variant infections.